SPMs
| SPM . | N . | Median time to SPM diagnosis, months (range) . | ASCT . | Gender . | On study . |
|---|---|---|---|---|---|
| Solid tumors (stage) | 6 | 35 (8-71) | |||
| Metastatic melanoma | 1 | 8 mo | No | M | On |
| Colon (IV) | 1 | 25 mo | No | M | On |
| Colon (III) | 1 | 31 mo | No | F | Off |
| Pancreas (II) | 1 | 39 mo | Yes | M | Off |
| Prostate (II) | 1 | 53 mo | No | M | On |
| Lung carcinoid (I) | 1 | 71 mo | Yes | F | Off |
| Hematologic tumors | 0 | ||||
| Basal cell carcinoma | 4 | 42 (5-64) | No | 2F, 2M | On |
| Squamous cell carcinoma | 2 | 29.5 (28-33) | No | 2M | On/Off |
| SPM . | N . | Median time to SPM diagnosis, months (range) . | ASCT . | Gender . | On study . |
|---|---|---|---|---|---|
| Solid tumors (stage) | 6 | 35 (8-71) | |||
| Metastatic melanoma | 1 | 8 mo | No | M | On |
| Colon (IV) | 1 | 25 mo | No | M | On |
| Colon (III) | 1 | 31 mo | No | F | Off |
| Pancreas (II) | 1 | 39 mo | Yes | M | Off |
| Prostate (II) | 1 | 53 mo | No | M | On |
| Lung carcinoid (I) | 1 | 71 mo | Yes | F | Off |
| Hematologic tumors | 0 | ||||
| Basal cell carcinoma | 4 | 42 (5-64) | No | 2F, 2M | On |
| Squamous cell carcinoma | 2 | 29.5 (28-33) | No | 2M | On/Off |
Invasive tumors were seen at a rate expected by SEER database. No hematologic malignancies were seen. No association noted with multiple variables analyzed.
F, female; M, male; SEER, Surveillance Epidemiology and End Results.